Lonza

The Lonza Japan team will be attending CPHI Japan 2025 in Tokyo from April 9th to 11th. Visit our booth #5N-08 and discuss with our team how we can work together to overcome your development and manufacturing challenges. Contact us if you want to schedule a meeting with the team: https://lnkd.in/dZvaTsmM #CPHIJAPAN #Lonza #CDMO #MakingtheMedicinesofTomorrow

Today we published our Annual Report 2024 and Sustainability Report 2024, giving a comprehensive overview of our progress towards our long-term business and sustainability goals.    In 2024, we redoubled our focus on our core CDMO business to deliver long-term value creation. Highlights included the unveiling of our One Lonza strategy at our Investor Update in December, and the addition of our Vacaville (US) site into our global network. We also continued to execute our ongoing organic investment program to enable future growth.   Sustainable business remains an ethical, social and commercial imperative for Lonza, and in 2024 we made progress in reducing our environmental impact with a combined focus on energy, greenhouse gases, water and waste. In 2025, we aim to deepen our understanding of climate-related impacts on our operations and enhance our pipeline of projects to drive sustainable value creation. Read the reports here: https://lnkd.in/daZvZwxa   #Lonza #CDMO #Growth #Sustainability #AnnualReport

Meeting the needs of our customers is at the core of everything we do. Our website has evolved, designed to support our One Lonza vision. Explore our three new business platforms, through a streamlined navigation that gives you the opportunity to explore our offerings and get in touch to build on our relationship. Visit our updated website today: www.lonza.com #Lonza #CDMO #PharmaceuticalManufacturing #Biotechnology #OneLonza

Join our presentation at Flow Chemistry Europe on 4th April in Málaga, Spain. Dominique M. Roberge, our #SmallMolecules expert from our Advanced Synthesis Business Platform, will present "Mini-Monoplant Technology for Pharmaceutical Manufacturing with Case Studies." Dominique will share real-life case studies on how Lonza’s innovative mini-monoplant technology, powered by continuous flow, can optimize chemical processes from early-phase development all the way to commercialization. This model is ideal for complex, potent, and specialized small molecule therapeutics that require rapid market entry. Don’t miss this opportunity to learn how Lonza’s flow chemistry capabilities and mini-monoplant approach are transforming pharmaceutical manufacturing by accelerating timelines and reducing costs. #FlowChemistry #DrugDevelopment #FCE25

"I have seen first-hand the drive and heart that CGT personnel bring to their work and the weight that rigorous training and collaboration carries in advancing CGT. My conversations with our team frequently touch on the opportunity to play a role in producing life-changing therapies for patients, which is a big motivator for them." Daniel Palmacci, Head of Specialized Modalities at Lonza, recently wrote an article for The Medicine Maker about how mentorship, professional development and open dialogue help build resilient cell and gene therapy teams. Read the full article here: https://lnkd.in/dtvXReT9

Today marks a major milestone for Lonza as we launch our simplified and streamlined operating model. Based on our new “One Lonza” vision and strategy, this transformation unites our core competencies to fulfil our vision to be a pioneer and world leader in the CDMO industry. The Lonza CDMO offering now comprises three new Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities. This organizational structure will help us to capture growth opportunities and scale our business, as we work to serve our customers and their patients. We also remain committed to finding the right moment to part ways with the Capsules & Health Ingredients business, in a way that ensures the business continues to operate outside of Lonza. Our “One Lonza” core business now has a single focus as a dedicated CDMO, united by our purpose to turn our customers’ break-through innovations into viable therapies and manufacture the medicines of tomorrow. Read more here: https://lnkd.in/e-kSDuuy   #Lonza #CDMO #Growth #PharmaceuticalManufacturing #Biotechnology

At this year’s 41st SCI Process Development Symposium (2–4 April 2025, Cambridge, UK), our #SmallMolecules expert, Simon Wagschal, will present ''Recent Examples of Flow Technology at Lonza.'' At Lonza, we employ continuous flow technology to enhance process robustness, increase product yield and consistency, and reduce production costs. If you're interested in how enabling technologies like flow chemistry can accelerate your drug development, join Simon’s talk and connect with our team at the symposium. #LonzaSM #WeWorkAsOne #FlowChemistry

Join Lonza's experts next week, as they explore strategies for minimizing your risk in RNA-lipid nanoparticle (LNP) encapsulation and drug product manufacturing 📅 31 March 🕝 11am EDT / 4pm CET Register here: https://lnkd.in/d_4yYdgm #Lonza #Biologics #Biotechnology

Join Diana Čekatauskaitė on 3 April at Innovation for Health 2025 in Rotterdam, Netherlands, where she will present "Synaffix Technology Toolbox: One-Stop-Shop for Best-in-Class Antibody Conjugates." As a Lonza company, Synaffix BV offers cutting-edge ADC technology that enables seamless, end-to-end development of best-in-class antibody-drug conjugates from early discovery to clinical development and commercial manufacturing. If you're attending, don’t miss the opportunity to connect with Diana and explore how Lonza and Synaffix can support your ADC development journey. #ADCs #drugdevelopment

"Exosomes can be exploited to deliver drugs to specific tissues across biological barriers and, given their physiological role, with a lower risk of triggering adverse immune reactions as compared to other organic or inorganic nanoparticles." Davide Zocco, Head of Exosomes Development at Lonza, speaks to PharmTech about the therapeutic potential of exosomes, and some of the challenges involved in their development. Read the full article here: https://lnkd.in/edH335EA #Lonza #PharmaceuticalManufacturing #AdvancedTherapies #Exosomes #Nanoparticles